Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?

导出 OA

翻译打印收藏纠错

作者： Noha,Nafee ^[1] ; Dina M,Gaber ^[2] ; Alaa,Abouelfetouh ^[3] ; Mustafa,Alseqely ^[4] ; Martin,Empting ^[5] ; Marc,Schneider ^[4]

作者单位： Department of Pharmaceutics, College of Pharmacy, Kuwait University, Safat, 13110, Kuwait. ^[1] Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. ^[2] Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, 1029, Egypt. ^[3] Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. ^[4] Department of Microbiology and Immunology, Faculty of Pharmacy, Alamein International University, Alamein, 5060335, Egypt. ^[5] Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Department of Antiviral and Antivirulence Drugs (AVID), Saarland University, Saarbrücken, 66123, Germany. ^[6] Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, 66123, Germany. ^[7]

关键词 Pseudomonas aeruginosa alginate lyase chitosan cystic fibrosis quorum-sensing inhibitors solid lipid nanoparticles